On April 16, 2025 OncoC4, Inc., a late-stage biopharmaceutical company developing novel medicines for cancer reported that it will present during the Showcase Session at the 2025 American Association for Cancer Research (AACR) (Free AACR Whitepaper) Oncology Industry Partnering Event being held April 24-25, 2025, in Chicago, Illinois (Press release, OncoC4, APR 16, 2025, View Source [SID1234655988]). The Showcase Session is a new addition to the 2025 program that features companies selected from a competitive application process.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We are pleased to be selected to share recent progress across our pipeline of best-in-class and first-in-class drugs targeting both validated and novel immune checkpoints at this year’s AACR (Free AACR Whitepaper) Showcase Session," said Yang Liu, PhD, Co-Founder, Chief Executive Officer and Chief Scientific Officer of OncoC4. "Our two lead wholly owned programs are advancing in the clinic including AI-081, a differentiated PD-1/VEGF bispecific antibody with stronger cooperative interactions and the potential for superior patient outcomes, and ONC-841, an anti-Siglec-10 antibody that promotes anti-tumor immunity by blocking the novel immune checkpoint implicated in tumor evasion. Both candidates have the potential to significantly impact the treatment landscape for solid tumors, and we look forward to initial dose-escalation data for both programs in advanced solid tumors in the second half of 2025."
Showcase Session Corporate Presentation Details
Date: Thursday, April 24, 2025
Time: 5:05 p.m. ET
Session: Showcase Session 2 (W192)
Presenter: Pan Pan, Senior Vice President of Business Development